An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.

Pancreatic ductal adenocarcinoma (PDAC) is a complex disease with significant intra-tumoral heterogeneity (ITH). Currently, no reliable PDAC tumor model is available that can present ITH profiles in a controlled manner. We develop an in vitro microfluidic tumor model mimicking the heterogeneous accumulation of key driver mutations of human PDAC using cancer cells derived from genetically engineered mouse models. These murine pancreatic cancer cell lines have KPC (Kras and Trp53 mutations) and KIC genotypes (Kras mutation and Cdkn2a deletion). Also, the KIC genotypes have two distinct phenotypes - mesenchymal or epithelial. The tumor model mimics the ITH of human PDAC to study the effects of ITH on the gemcitabine response. The results show gemcitabine resistance induced by ITH. Remarkably, it shows that cancer cell-cell interactions induce the gemcitabine resistance potentially through epithelial-mesenchymal-transition. The tumor model can provide a useful testbed to study interaction mechanisms between heterogeneous cancer cell subpopulations.

[1]  P. Martinez,et al.  Assessing Cell Activities rather than Identities to Interpret Intra-Tumor Phenotypic Diversity and Its Dynamics , 2020, iScience.

[2]  B. Han,et al.  A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma. , 2020, Small.

[3]  Steven J. M. Jones,et al.  Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution , 2020, Nature Genetics.

[4]  Linda T. Nieman,et al.  Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma , 2019, Proceedings of the National Academy of Sciences.

[5]  Seungwon Jung,et al.  Co-culture of functionally enriched cancer stem-like cells and cancer-associated fibroblasts for single-cell whole transcriptome analysis. , 2019, Integrative biology : quantitative biosciences from nano to macro.

[6]  Jihoon Ko,et al.  Tumor spheroid-on-a-chip: a standardized microfluidic culture platform for investigating tumor angiogenesis. , 2019, Lab on a chip.

[7]  Jake June-Koo Lee,et al.  A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling , 2019, Science Advances.

[8]  Martin J. Aryee,et al.  Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer , 2019, Cell.

[9]  T. Andresen,et al.  A tumorsphere model of glioblastoma multiforme with intratumoral heterogeneity for quantitative analysis of cellular migration and drug response. , 2019, Experimental cell research.

[10]  Y. S. Zhang,et al.  A Tumor‐on‐a‐Chip System with Bioprinted Blood and Lymphatic Vessel Pair , 2019, Advanced functional materials.

[11]  Deok‐Ho Kim,et al.  Microphysiological Systems as Enabling Tools for Modeling Complexity in the Tumor Microenvironment and Accelerating Cancer Drug Development , 2019, Advanced Functional Materials.

[12]  Donald E. Ingber,et al.  Modelling cancer in microfluidic human organs-on-chips , 2019, Nature Reviews Cancer.

[13]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[14]  Shuichi Takayama,et al.  Engineering cell heterogeneity into organs-on-a-chip. , 2018, Lab on a chip.

[15]  Cyriac Kandoth,et al.  Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer , 2018, Cell.

[16]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[17]  Peter Ertl,et al.  Recent advances in microfluidic technologies for cell-to-cell interaction studies. , 2018, Lab on a chip.

[18]  L. Wood,et al.  New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. , 2017, Advances in anatomic pathology.

[19]  Ick Chan Kwon,et al.  Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Arturo Araujo,et al.  Cancer heterogeneity: converting a limitation into a source of biologic information , 2017, Journal of Translational Medicine.

[21]  J. Gjerstad,et al.  MicroRNA-223 demonstrated experimentally in exosome-like vesicles is associated with decreased risk of persistent pain after lumbar disc herniation , 2017, Journal of Translational Medicine.

[22]  M. Bikson,et al.  Higher-order power harmonics of pulsed electrical stimulation modulates corticospinal contribution of peripheral nerve stimulation , 2017, Scientific Reports.

[23]  M. Falasca,et al.  Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer , 2017, World journal of gastrointestinal oncology.

[24]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[25]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[26]  Hanry Yu,et al.  Heralding a new paradigm in 3D tumor modeling. , 2016, Biomaterials.

[27]  M. Korc,et al.  Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. , 2016, Cancer letters.

[28]  Stephanie J Hachey,et al.  3D microtumors in vitro supported by perfused vascular networks , 2016, Scientific Reports.

[29]  C. Iacobuzio-Donahue,et al.  p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells , 2016, Oncogene.

[30]  C. Iacobuzio-Donahue,et al.  Pancreatic cancer biology and genetics from an evolutionary perspective , 2016, Nature Reviews Cancer.

[31]  L. Pagani,et al.  Corrigendum: Global diversity in the TAS2R38 bitter taste receptor: revisiting a classic evolutionary PROPosal , 2016, Scientific Reports.

[32]  Brett S. Klosterhoff,et al.  Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip. , 2016, Molecular pharmaceutics.

[33]  Qiangbin Wang,et al.  Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature‐Targeted Strategy , 2016 .

[34]  S. Hingorani,et al.  Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. , 2016, Gastroenterology.

[35]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[36]  N. Bhowmick,et al.  Role of EMT in Metastasis and Therapy Resistance , 2016, Journal of clinical medicine.

[37]  J. Kleeff,et al.  Pancreatic cancer , 1988, Nature Reviews Disease Primers.

[38]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[39]  Li Ying,et al.  Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform , 2015, PloS one.

[40]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[41]  Kinam Park,et al.  Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[42]  D. Richel,et al.  Protease‐activated receptor‐1 drives pancreatic cancer progression and chemoresistance , 2014, International journal of cancer.

[43]  R. Jesenofsky,et al.  Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.

[44]  Charles Swanton,et al.  Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.

[45]  Daniel Öhlund,et al.  Fibroblast heterogeneity in the cancer wound , 2014, The Journal of experimental medicine.

[46]  P. Greenberg,et al.  Stromal reengineering to treat pancreas cancer. , 2014, Carcinogenesis.

[47]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[48]  Yolonda L Colson,et al.  Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations. , 2014, Biomaterials.

[49]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[50]  Kornelia Polyak,et al.  Cellular heterogeneity and molecular evolution in cancer. , 2013, Annual review of pathology.

[51]  Paolo P. Provenzano,et al.  Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer , 2013, British Journal of Cancer.

[52]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[53]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[54]  Melody A Swartz,et al.  Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. , 2012, Physiological reviews.

[55]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[56]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[57]  T. Hudson,et al.  The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[58]  M. Korc,et al.  A KrasG12D-Driven Genetic Mouse Model of Pancreatic Cancer Requires Glypican-1 for Efficient Proliferation and Angiogenesis , 2011, Oncogene.

[59]  Christopher Moraes,et al.  Organs-on-a-Chip: A Focus on Compartmentalized Microdevices , 2011, Annals of Biomedical Engineering.

[60]  M. Korc,et al.  A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells , 2011, Cancer biology & therapy.

[61]  Dietmar W. Hutmacher,et al.  Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. , 2010, Biomaterials.

[62]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[63]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[64]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[65]  Zhiwei Wang,et al.  Pancreatic cancer stem cells and EMT in drug resistance and metastasis. , 2009, Minerva chirurgica.

[66]  Zhiwei Wang,et al.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. , 2009, Cancer research.

[67]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[68]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[69]  E. Neilson,et al.  Biomarkers for epithelial-mesenchymal transitions. , 2009, The Journal of clinical investigation.

[70]  Zhiwei Wang,et al.  Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. , 2009, Cancer research.

[71]  C. Gottardi,et al.  Cadherins and cancer: how does cadherin dysfunction promote tumor progression? , 2008, Oncogene.

[72]  Mina J Bissell,et al.  Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. , 2008, Seminars in cancer biology.

[73]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[74]  F. Pampaloni,et al.  The third dimension bridges the gap between cell culture and live tissue , 2007, Nature Reviews Molecular Cell Biology.

[75]  D. V. Von Hoff,et al.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma , 2007, Molecular Cancer Therapeutics.

[76]  Alexandra P. Vamvakidou,et al.  Heterogeneous Breast Tumoroids: An In Vitro Assay for Investigating Cellular Heterogeneity and Drug Delivery , 2007, Journal of biomolecular screening.

[77]  I. Tannock,et al.  The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. , 2006, Cancer research.

[78]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[79]  M. Löhr,et al.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.

[80]  G. Imreh,et al.  Sequential degradation of proteins from the nuclear envelope during apoptosis. , 2001, Journal of cell science.

[81]  S. Kern.  Molecular genetic alterations in ductal pancreatic adenocarcinomas. , 2000, The Medical clinics of North America.